WO2023168830A1 - 一种hemtac小分子降解剂及其应用 - Google Patents
一种hemtac小分子降解剂及其应用 Download PDFInfo
- Publication number
- WO2023168830A1 WO2023168830A1 PCT/CN2022/093374 CN2022093374W WO2023168830A1 WO 2023168830 A1 WO2023168830 A1 WO 2023168830A1 CN 2022093374 W CN2022093374 W CN 2022093374W WO 2023168830 A1 WO2023168830 A1 WO 2023168830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- protein
- hsp90
- small molecule
- equiv
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 title abstract description 30
- 238000006731 degradation reaction Methods 0.000 title abstract description 30
- 150000003384 small molecules Chemical class 0.000 title abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 101710113864 Heat shock protein 90 Proteins 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 206010061218 Inflammation Diseases 0.000 claims abstract description 11
- 230000004054 inflammatory process Effects 0.000 claims abstract description 11
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims description 58
- 239000003446 ligand Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 9
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 claims description 6
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 claims description 6
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 6
- 101150040459 RAS gene Proteins 0.000 claims description 6
- 101150076031 RAS1 gene Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 102000016914 ras Proteins Human genes 0.000 claims description 6
- 230000022131 cell cycle Effects 0.000 claims description 5
- 239000005414 inactive ingredient Substances 0.000 claims description 5
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 3
- 229960004390 palbociclib Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- -1 stereoisomers Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 18
- 230000001939 inductive effect Effects 0.000 abstract description 6
- 102000044159 Ubiquitin Human genes 0.000 abstract description 4
- 108090000848 Ubiquitin Proteins 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 4
- 230000034512 ubiquitination Effects 0.000 abstract description 4
- 238000010798 ubiquitination Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 68
- 239000000243 solution Substances 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 27
- 239000007787 solid Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000001308 synthesis method Methods 0.000 description 8
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 7
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 7
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 7
- 229940125846 compound 25 Drugs 0.000 description 7
- 230000017854 proteolysis Effects 0.000 description 7
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 6
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 6
- 108010026668 snake venom protein C activator Proteins 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
- 229940125758 compound 15 Drugs 0.000 description 5
- 229940126086 compound 21 Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000005431 Molecular Chaperones Human genes 0.000 description 4
- 108010006519 Molecular Chaperones Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000001064 degrader Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 3
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003127 anti-melanomic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- TZZDVPMABRWKIZ-XMOGEVODSA-N (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-XMOGEVODSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000015367 CRBN Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- CLCTZVRHDOAUGJ-UHFFFAOYSA-N N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide Chemical compound FC1=CC2=C(C=C1N1CCN(CC3CCN(CC3)C3=CC=C(N=N3)C(=O)NC3CCC(CC3)OC3=CC(Cl)=C(C=C3)C#N)CC1)C(=O)N(C1CCC(=O)NC1=O)C2=O CLCTZVRHDOAUGJ-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 101710092482 Protein kinase 4 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- STOASOOVVADOKH-UHFFFAOYSA-N but-3-ynyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCC#C)C=C1 STOASOOVVADOKH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011864 protein degradation method Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- IRUJRVAXEALDLJ-UHFFFAOYSA-N tert-butyl 4-[2-(methylamino)ethyl]piperazine-1-carboxylate Chemical compound CNCCN1CCN(C(=O)OC(C)(C)C)CC1 IRUJRVAXEALDLJ-UHFFFAOYSA-N 0.000 description 1
- VULKFBHOEKTQSF-UHFFFAOYSA-N tert-butyl n-[2-(2-aminoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCN VULKFBHOEKTQSF-UHFFFAOYSA-N 0.000 description 1
- OCUICOFGFQENAS-UHFFFAOYSA-N tert-butyl n-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCOCCN OCUICOFGFQENAS-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- the invention belongs to the field of biomedicine technology, and specifically relates to a HEMTAC small molecule degradation agent and its application.
- HSP90 heat shock protein 90
- HSP90 The heat shock protein 90 family is a type of ATP-dependent molecular chaperone with a molecular weight of approximately 90kDa.
- HSP90 exists in cells in the form of dimers. The dimerization of HSP90 is necessary for its intracellular functions. Under non-stress conditions, the expression of HSP90 accounts for approximately 1% to 2% of the total intracellular protein. , which is thousands of times the average protein content; under stress conditions, the content of HSP90 can increase to 4% to 6% of the total cellular protein.
- HSP90 proteins are divided into HSP90 ⁇ (inducible) and HSP90 ⁇ (constitutive). The expression of HSP90 ⁇ increases after being induced by heat, which is related to maintaining cell homeostasis under stress conditions; while HSP90 ⁇ is continuously expressed and must exist in mammals, and is related to the life activities of mammals.
- HSP90 can activate different substrate proteins and then participate in the regulation of various life activities.
- molecular chaperones can activate newly synthesized proteins, assemble and depolymerize molecular complexes, help refold abnormally folded proteins, coordinate with the ubiquitin-proteasome system to regulate and degrade misfolded proteins, etc.
- heat shock protein family is closely related to tumors. The expression of HSP90 is abnormally increased in tumor cells induced by some oncogenes and their products, and is involved in tumor growth, invasion, metastasis, etc.
- the purpose of the present invention is to provide a HEMTAC small molecule degradation agent based on HSP90 that induces target protein degradation and its application.
- HSP90 which has stable client proteins, can utilize the ubiquitin-proteasome system to degrade erroneous proteins, and is highly expressed in tumor cells, the present invention designs and develops a new protein degradation technology, and names it heat shock protein 90 mediator.
- a first aspect of the present invention provides a compound having the structure described in the following formula (I):
- R1 is the ligand/binding compound of the target protein
- R2 is the ligand of HSP90
- L is a connecting chain, and the R1 and R2 are connected through L.
- HSP90 heat shock protein 90
- HEMTACs targeting chimeras
- Small molecule HEMTACs contain three parts: a ligand that binds to the target protein, a linker chain, and a ligand that binds to HSP90.
- the linking chain connects two ligands to form small molecule HEMTACs.
- small molecule HEMTACs can induce the formation of HSP90-HEMTAC-target protein ternary complexes, position the target protein in a spatially favorable position that is mistakenly recognized as an "abnormal" protein by HSP90, and then introduce it In the ubiquitin-proteasome system and leading to the degradation of target proteins, HEMTACs are released and participate in the next degradation cycle. Therefore, small molecule HEMTACs have a catalytic role in inducing ubiquitin and degradation of target proteins.
- the target proteins include, but are not limited to, kinases, G protein-coupled receptors, transcription factors, phosphatases and RAS superfamily members;
- said R1 is selected from: compounds targeting kinases, G protein-coupled receptors, transcription factors, phosphatases and members of the RAS superfamily.
- the R1 is Palbociclib.
- the R2 is the ligand BIIB021 of HSP90 or a derivative thereof.
- the compounds also include pharmaceutically acceptable salts, stereoisomers, esters, prodrugs, solvates and deuterated compounds thereof.
- a second aspect of the present invention provides the use of the above compounds in the preparation of drugs for tumors, inflammation, and immune-related diseases.
- the disease may also be a disease related to cell cycle-dependent protein kinase 4 and 6 (CDK4/6).
- a third aspect of the present invention provides a pharmaceutical composition comprising the above compound.
- a fourth aspect of the present invention provides a pharmaceutical preparation comprising the above compound and at least one pharmaceutically acceptable pharmaceutical inactive ingredient.
- the above pharmaceutical composition or pharmaceutical preparation can be used to treat tumors, inflammation, and immune-related diseases, especially diseases related to cell cycle-dependent protein kinases 4 and 6 (CDK4/6).
- a fifth aspect of the present invention provides a method for treating tumors, inflammation, and immune-related diseases, which method includes administering a therapeutically effective amount of the above-mentioned compound, pharmaceutical composition, or pharmaceutical preparation to a subject.
- the above technical solution reports for the first time a HSP90-based HEMTAC small molecule degrader that induces target protein degradation and its application.
- the present invention found through research that the HEMTAC small molecule degrader can induce the formation of HSP90-HEMTAC-target protein ternary complex, and position the target protein in a position that is conducive to being mistakenly recognized as an "abnormal" protein by HSP90. , which are then introduced into the ubiquitin-proteasome system and lead to the degradation of the target protein.
- HEMTACs are released and participate in the next degradation cycle. Therefore, they have a catalytic role in inducing ubiquitin and degradation of the target protein, which can be used for therapy. It is related to diseases such as tumors, inflammation, and immunity, so it has good prospects for practical application.
- Figure 1 is a functional schematic diagram of HSP90 chaperones and a schematic diagram of the protein degradation mechanism of small molecule HEMTACs.
- Figure 2 shows the surface plasmon resonance (SPR) method to determine the binding affinity of compounds to HSP90 ⁇ .
- Figure 3 shows the effect of HEMTAC 26 on CDK4 and CDK6 protein levels in B16F10 cells at different concentrations and times.
- Figure 4 shows the anti-tumor activity of small molecule HEMTAC 26 in the mouse B16F10 melanoma model.
- the experimental results show that small molecule HEMTAC 26 has significant anti-melanoma effects in vivo.
- R1 is the ligand/binding compound of the target protein
- R2 is the ligand of HSP90
- L is a connecting chain, and the R1 and R2 are connected through L.
- HSP90 heat shock protein 90
- HEMTACs heat shock protein 90-mediated targeting chimeras
- Small molecule HEMTACs contain three parts: a ligand that binds to the target protein, a linker chain, and a ligand that binds to HSP90.
- the linking chain connects two ligands to form small molecule HEMTACs.
- small molecule HEMTACs can induce the formation of HSP90-HEMTAC-target protein ternary complexes, position the target protein in a spatially favorable position that is mistakenly recognized as an "abnormal" protein by HSP90, and then introduce it In the ubiquitin-proteasome system and leading to the degradation of target proteins, HEMTACs are released and participate in the next degradation cycle. Therefore, small molecule HEMTACs have a catalytic role in inducing ubiquitin and degradation of target proteins.
- the target proteins include, but are not limited to, kinases, G protein-coupled receptors, transcription factors, phosphatases and RAS superfamily members;
- said R1 is selected from: compounds targeting kinases, G protein-coupled receptors, transcription factors, phosphatases and members of the RAS superfamily.
- the R1 is Palbociclib.
- the R2 is the ligand BIIB021 of HSP90 or a derivative thereof,
- HSP90 ligand BIIB021 The general formula of the HSP90 ligand BIIB021 or its derivative is as follows:
- the compound includes any one or more of the following:
- the compound further includes pharmaceutically acceptable salts, stereoisomers, esters, prodrugs, solvates and deuterated compounds thereof.
- the disease may also be a disease related to cell cycle-dependent protein kinases 4 and 6 (CDK4/6).
- a pharmaceutical composition which contains the above compound.
- the pharmaceutical composition can be used alone or in combination with other types of drugs to treat tumors, inflammation, immunity and other diseases.
- a pharmaceutical preparation which contains the above-mentioned compound and at least one pharmaceutically acceptable pharmaceutical inactive ingredient.
- the pharmaceutical inactive ingredients may be carriers, excipients, diluents, etc. commonly used in pharmaceuticals. Moreover, it can be prepared into dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, etc., for oral use, external preparations, suppositories, and sterile injection solutions according to usual methods. .
- non-pharmaceutical active ingredients such as carriers, excipients and diluents that may be included are well known in the art, and those of ordinary skill in the art can determine that they meet clinical standards.
- the carrier, excipient and diluent include but are not limited to lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, Starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc Powder, magnesium stearate and mineral oil, etc.
- the medicament of the present invention can be administered into the body in a known manner. Delivery to the tissue of interest may occur, for example, via intravenous systemic delivery or local injection. Administration may optionally be via intravenous, transdermal, intranasal, mucosal or other delivery methods. Such administration may be via a single dose or multiple doses. It will be understood by those skilled in the art that the actual dosage to be administered in the present invention may vary to a large extent depending on a variety of factors, such as the target cell, the type of organism or its tissue, the general condition of the subject to be treated, the administration Drug routes, administration methods, etc.
- the drug administration subjects can be humans and non-human mammals, such as mice, rats, guinea pigs, rabbits, dogs, monkeys, orangutans, etc.
- the above pharmaceutical composition or pharmaceutical preparation can be used to treat tumors, inflammation, and immune-related diseases, especially diseases related to cell cycle-dependent protein kinases 4 and 6 (CDK4/6).
- a fifth aspect of the present invention provides a method for treating tumors, inflammation, and immune-related diseases, which method includes administering a therapeutically effective amount of the above-mentioned compound, pharmaceutical composition, or pharmaceutical preparation to a subject.
- the subject refers to an animal that has been the subject of treatment, observation or experiment, preferably a mammal, and most preferably a human.
- the “therapeutically effective amount” refers to the amount of active compounds or agents, including the compounds of the present invention, that can cause the biological or biological effects of tissue systems, animals or humans pursued by researchers, veterinarians, doctors or other medical personnel. Medical response, which includes alleviation or partial alleviation of symptoms of the disease, syndrome, condition or disorder being treated.
- Dissolve compound 1 (2g, 11.86mmol, 1.0equiv.) in 20mL pyridine, then add trimethylacetyl chloride (4.45mL, 35.59mmol, 3equiv.), and stir at room temperature overnight to obtain N(2) monoacylation and Mixture of N(2) and N(7) bis-acylation.
- the solvent was removed, and the residue was dissolved in a mixed solvent of ammonia (25% NH 3 , 5 mL) and methanol (20 mL), and stirred at room temperature for 30 minutes to selectively cleave the pivaloyl group at the N (7) position.
- the reaction solution was heated to 75°C and stirred for 3 hours.
- the reaction solution was filtered through celite, washed with ethyl acetate, and then the filtrate was diluted with 100 mL of ethyl acetate.
- the organic phase was washed with water (40 mL ⁇ 3) and brine (40 mL ⁇ 3), and dried over anhydrous Na 2 SO 4 .
- compound 13 (300 mg, 593.38 ⁇ mol, 1.0 equiv.) and 2-(2-(2-aminoethoxy)ethoxy)ethylcarbamic acid tert-butyl ester (176.82 mg, 712.06 ⁇ mol, 1.2 equiv.) was used as raw material to obtain 310 mg of compound 17 as a yellow solid, with a yield of 71%.
- Example 7 Surface plasmon resonance (SPR) method to determine the binding affinity of compounds to HSP90 ⁇
- start detection change the buffer to PBS (pH 7.4) containing 1% DMSO, set the analyte binding time to 120s, the flow rate to 30 ⁇ L/min; the dissociation time to 300s, the flow rate to 30 ⁇ L/min; regeneration The time is 30s and the flow rate is 30 ⁇ L/min.
- PBS pH 7.4 containing 1% DMSO
- the intracellular CDK4 and CDK6 protein levels were determined by Western blot experiment.
- extract cellular proteins and perform protein quantification lyse cells with RIPA cell lysis buffer (plus protease inhibitors), collect proteins, and quantify them with a BCA protein quantitative assay kit to the same concentration.
- Protein denaturation Place the protein in a 100°C water bath for 8 minutes to denature the protein.
- Load the sample and run the gel The sample volume per well is generally 20 ⁇ L.
- the electrophoresis voltage of the upper stacking gel is 75V
- the electrophoresis voltage of the lower separation gel is 120V.
- Film transfer Use a wet film transfer instrument for film transfer.
- the PVDF membrane must be soaked in methanol in advance, with a constant current of 250mA and a film transfer time of 90 minutes.
- Blocking Place the PVDF membrane in BSA blocking solution for 1 hour (slow shaking on a shaker).
- Incubate the primary antibody Dilute the primary antibody according to the instructions, add the primary antibody, and incubate at 4°C overnight.
- Membrane washing Wash 3 times with TBST membrane washing solution, 10 minutes each time.
- Incubate the secondary antibody After adding the secondary antibody, incubate on a shaking table at room temperature for 1 hour.
- Membrane washing Wash 3 times with TBST membrane washing solution, 10 minutes each time.
- Exposure Mix equal volumes of ECL developer A and B and perform exposure.
- B16F10 cells (10 6 cells/mouse) were subcutaneously injected into the forelimb axilla of C57BL/6 mice to establish a mouse B16F10 melanoma xenograft model.
- Compounds were injected intraperitoneally every day for two consecutive weeks, and mouse body weight and tumor volume were measured every two days.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于生物医药技术领域,具体涉及一种HEMTAC小分子降解剂及其应用。本发明通过研究发现,所述HEMTAC小分子降解剂可以诱导HSP90-HEMTAC-靶蛋白三元络合物的形成,将靶蛋白定位在空间上有利于被HSP90错误地识别为"异常"蛋白质的位置,随后将其导入泛素-蛋白酶体系统中,并导致靶蛋白的降解,HEMTACs被释放并参与下一个降解循环,因此,其在诱导靶蛋白泛素和降解方面具有催化作用,从而可用于治疗与肿瘤、炎症、免疫等相关疾病,因此具有良好的实际应用之前景。
Description
本发明属于生物医药技术领域,具体涉及一种HEMTAC小分子降解剂及其应用。
本发明背景技术中公开的信息仅仅旨在增加对本发明的总体背景的理解,而不必然被视为承认或以任何形式暗示该信息构成已经成为本领域一般技术人员所公知的现有技术。
在对药物化学的不断探索中,新的靶向疾病驱动蛋白的策略正在不断的被开发,其中由小分子诱导的靶蛋白降解策略是近年来最值得关注的,该策略可以靶向无活性位点或者不可成药的蛋白靶标,使得降解任意一种蛋白成为了可能。目前开发的降解技术主要有蛋白水解靶向嵌合体(proteolysis-targeting chimeras,PROTACs),溶酶体靶向嵌合体(lysosome-targeting chimeras,LYTACs)和基于抗体的PROTACs(antibody-based PROTACs,AbTACs)。PROTAC技术相关的候选药物ARV-110和ARV-471已进入临床II期,PROTAC技术主要针对细胞内蛋白,而LYTAC和AbTAC技术可以降解细胞外分泌蛋白和膜蛋白。蛋白降解技术在靶向不可成药靶点和疾病治疗方面展现出了非常大的潜力。
虽然这些新的降解技术的出现可以克服小分子抑制剂的局限性,同时,新兴的降解技术也存在一些局限性,其可能导致在许多组织和器官中不参与疾病过程的靶蛋白的降解,从而在治疗过程中可能导致严重的副作用。另外一方面,小分子PROTAC通过“劫持”E3连接酶发挥其降解作用,然而已有研究表明基于VHL和CRBN的小分子PROTAC在细胞中会引起脱靶效应和耐药机制的产生。因此,迫切需要扩大靶向降解技术的范围,开发新的蛋白降解技术。
热休克蛋白90(heat shock protein 90,HSP90)家族是一类ATP依赖的分子伴侣,分子量约90kDa。HSP90以二聚体形式存在于细胞中,HSP90的二聚化是其行使细胞内功能所必须的,在非应激状态下,HSP90的表达量约占细胞内蛋白总量的1%~2%,是蛋白平均含量的数千倍;在应激条件下,HSP90的含量可升高到细胞蛋白总量的4%~6%。在人细胞中,HSP90蛋白分为HSP90α(诱导型)和HSP90β(组成型)。HSP90α在受到热诱导后表达增加,与压力条件下维持细胞稳态相关;而HSP90β可持续表达且在哺乳动物体内必须存在,与哺乳动物的生命活动相关。
作为一种重要的分子伴侣,HSP90可以激活不同的底物蛋白,进而参与多种生命活动的调节。为了使蛋白质行使其正常的生物学功能,分子伴侣可以激活新合成的蛋白质、组装和解聚分子复合物、帮助异常折叠的蛋白质重新折叠、与泛素-蛋白酶体系统协同调节并降解错误折叠蛋白等。此外,研究发现热休克蛋白家族与肿瘤关系密切,HSP90在一些癌基因及其产物诱导的肿瘤细胞中表达异常增高,并参与肿瘤的生长、侵袭、转移等。
发明内容
本发明的目的在于提供一种基于HSP90的诱导靶蛋白降解的HEMTAC小分子降解剂及其应用。本发明根据HSP90具有稳定客户蛋白,能够利用泛素-蛋白酶体系统降解错误蛋白,并在肿瘤细胞中高表达等特点,设计开发一种新型的蛋白降解技术,并将其命名为热休克蛋白90介导的靶向嵌合体(heat shock protein 90(HSP90)-mediated targeting chimeras,HEMTACs)。基于上述研究成果,从而完成本发明。
本发明的技术方案如下:
本发明的第一个方面,提供一种化合物,其具有如下式(I)所述结构:
R
1—L—R
2
式(I)
其中:
(a)R1是靶蛋白的配体/结合物;
(b)R2是HSP90的配体;
(c)L是连接链,所述R1和R2通过L连接起来。
上述化合物实际为一种热休克蛋白90介导的靶向嵌合体(heat shock protein 90(HSP90)-mediated targeting chimeras,HEMTACs)小分子降解剂。
小分子HEMTACs包含三个部分:与靶蛋白结合的配体、连接链和与HSP90结合的配体。连接链连接两个配体构成小分子HEMTACs。和PROTAC技术类似,小分子HEMTACs可以诱导HSP90-HEMTAC-靶蛋白三元络合物的形成,将靶蛋白定位在空间上有利于被HSP90错误地识别为“异常”蛋白质的位置,随后将其导入泛素-蛋白酶体系统中,并导致靶蛋白的降解,HEMTACs被释放并参与下一个降解循环,因此,小分子HEMTACs在诱导靶蛋白泛素和降解方面具有催化作用。
所述靶蛋白包括但不限于激酶、G蛋白偶联受体、转录因子、磷酸酶及RAS超家族成员;
因此,所述R1选自:靶向以下的化合物:激酶、G蛋白偶联受体、转录因子、磷酸酶及RAS超家族成员。
具体的,所述R1是帕博西尼(Palbociclib)。
所述R2是HSP90的配体BIIB021或其衍生物。
所述化合物还包括其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物。
本发明的第二个方面,提供上述化合物在制备肿瘤、炎症、免疫相关疾病药物中的应用。
进一步的,所述疾病还可以是与细胞周期依赖性蛋白激酶4和6(CDK4/6)相关的疾病。
本发明的第三个方面,提供一种药物组合物,其包含上述化合物。
本发明的第四个方面,提供一种药物制剂,其包含上述化合物和至少一种药学上可接受的药物非活性成分。
显而易见的,上述药物组合物或药物制剂可用于治疗肿瘤、炎症、免疫相关疾病,特别是与细胞周期依赖性蛋白激酶4和6(CDK4/6)相关的疾病。
本发明的第五个方面,提供一种治疗肿瘤、炎症、免疫相关疾病的方法,所述方法包括向受试者施用治疗有效量的上述化合物、药物组合物或药物制剂。
上述一个或多个技术方案的有益技术效果:
上述技术方案首次报道了一种基于HSP90的诱导靶蛋白降解的HEMTAC小分子降解剂及其应用。本发明通过研究发现,所述HEMTAC小分子降解剂可以诱导HSP90-HEMTAC-靶蛋白三元络合物的形成,将靶蛋白定位在空间上有利于被HSP90错误地识别为“异常”蛋白质的位置,随后将其导入泛素-蛋白酶体系统中,并导致靶蛋白的降解,HEMTACs被释放并参与下一个降解循环,因此,其在诱导靶蛋白泛素和降解方面具有催化作用,从而可用于治疗与肿瘤、炎症、免疫等相关疾病,因此具有良好的实际应用之前景。
构成本发明的一部分的说明书附图用来提供对本发明的进一步理解,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。
图1为HSP90伴侣分子的功能示意图及小分子HEMTACs降解蛋白机制示意图。
图2为表面等离子共振法(SPR)测定化合物与HSP90α的结合亲和力。
图3为HEMTAC 26在不同的浓度和时间对B16F10细胞中CDK4和CDK6蛋白水平的影响。
图4为小分子HEMTAC 26在小鼠B16F10黑色素瘤模型中的抗肿瘤活性,实验结果表明小分子HEMTAC 26具有显著的体内抗黑色素瘤的作用。
应该指出,以下详细说明都是例示性的,旨在对本发明提供进一步的说明。除非另有指明,本文使用的所有技术和科学术语具有与本发明所属技术领域的普通技术人员通常理解的相同含义。
需要注意的是,这里所使用的术语仅是为了描述具体实施方式,而非意图限制根据本发明的示例性实施方式。如在这里所使用的,除非上下文另外明确指出,否则单数形式也意图包括复数形式,此外,还应当理解的是,当在本说明书中使用术语“包含”和/或“包括”时,其指明存在特征、步骤、操作、器件、组件和/或它们的组合。
现结合具体实例对本发明作进一步的说明,以下实例仅是为了解释本发明,并不对其内容进行限定。如果实施例中未注明的实验具体条件,通常按照常规条件,或按照试剂公司所推荐的条件;下述实施例中所用的试剂、耗材等,如无特殊说明,均可从商业途径得到。
本发明的一个典型具体实施方式中,提供一种化合物,其具有如下式(I)所述结构:
R
1—L—R
2
式(I)
其中:
(a)R1是靶蛋白的配体/结合物;
(b)R2是HSP90的配体;
(c)L是连接链,所述R1和R2通过L连接起来。
上述化合物实际为一种热休克蛋白90介导的靶向嵌合体(heat shock protein 90(HSP90)-mediated targeting chimeras,HEMTACs)小分子降解剂。小分子HEMTACs包含三个部分:与靶蛋白结合的配体、连接链和与HSP90结合的配体。连接链连接两个配体构成小分子HEMTACs。和PROTAC技术类似,小分子HEMTACs可以诱导HSP90-HEMTAC-靶蛋白三元络合物的形成,将靶蛋白定位在空间上有利于被HSP90错误地识别为“异常”蛋白质的位置,随后将其导入泛素-蛋白酶体系统中,并导致靶蛋白的降解,HEMTACs被释放并参与下一个降解循环,因此,小分子HEMTACs在诱导靶蛋白泛素和降解方面具有催化作用。
所述靶蛋白包括但不限于激酶、G蛋白偶联受体、转录因子、磷酸酶及RAS超家族成员;
因此,所述R1选自:靶向以下的化合物:激酶、G蛋白偶联受体、转录因子、磷酸酶及RAS超家族成员。
具体的,所述R1是帕博西尼(Palbociclib)。
所述R2是HSP90的配体BIIB021或其衍生物,
所述HSP90的配体BIIB021或其衍生物的通式如下所示:
本发明的又一具体实施方式中,所述化合物包括如下任意一种或多种:
本发明的又一具体实施方式中,所述化合物还包括其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物。
本发明的又一具体实施方式中,提供上述化合物在制备肿瘤、炎症、免疫相关疾病药物中的应用。
本发明的又一具体实施方式中,所述疾病还可以是与细胞周期依赖性蛋白激酶4和6(CDK4/6)相关的疾病。
本发明的又一具体实施方式中,提供一种药物组合物,其包含上述化合物。所述药物组合物可单独使用,或与其他种类的药物联合使用,用于治疗肿瘤、炎症、免疫等疾病。
本发明的又一具体实施方式中,提供一种药物制剂,其包含上述化合物和至少一种药学上可接受的药 物非活性成分。
所述药物非活性成分可以是药学上通常使用的载体、赋形剂及稀释剂等。而且,根据通常的方法,可以制作成粉剂、颗粒剂、片剂、胶囊剂、混悬剂、乳剂、糖浆剂、喷雾剂等的口服剂、外用剂、栓剂及无菌注射溶液形式的剂型使用。
所述可以包含的载体、赋形剂及稀释剂等非药物活性成分在领域内是熟知的,本领域普通技术人员能够确定其符合临床标准。
本发明的又一具体实施方式中,所述载体、赋形剂及稀释剂包括但不限于有乳糖、葡萄糖、蔗糖、山梨糖醇、甘露醇、木糖醇、赤藓糖醇、麦芽糖醇、淀粉、阿拉伯胶、藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石粉、硬脂酸镁和矿物油等。
本发明的又一具体实施方式中,本发明的药物可通过已知的方式施用至体内。例如通过静脉全身递送或者局部注射递送到感兴趣组织中。可选地经由静脉内、经皮、鼻内、粘膜或其他递送方法进行施用。这样的施用可以经由单剂量或多剂量来进行。本领域技术人员理解的是,本发明中有待施用的实际剂量可以在很大程度上取决于多种因素而变化,如靶细胞、生物类型或其组织、待治疗受试者的一般状况、给药途径、给药方式等等。
本发明的又一具体实施方式中,所述药物施用对象可以是人和非人哺乳动物,如小鼠、大鼠、豚鼠、兔、狗、猴、猩猩等。
显而易见的,上述药物组合物或药物制剂可用于治疗肿瘤、炎症、免疫相关疾病,特别是与细胞周期依赖性蛋白激酶4和6(CDK4/6)相关的疾病。
本发明的第五个方面,提供一种治疗肿瘤、炎症、免疫相关疾病的方法,所述方法包括向受试者施用治疗有效量的上述化合物、药物组合物或药物制剂。
所述受试者是指已经是治疗、观察或实验的对象的动物,优选指哺乳动物,最优选指人。
所述“治疗有效量”是指包括本发明化合物在内的活性化合物或药剂的量,该量可引起研究者、兽医、医生或其他医疗人员所追求的组织系统、动物或人的生物学或医学响应,这包括减轻或部分减轻受治疗的疾病、综合征、病症或障碍的症状。
本领域的研究者、兽医、医生或其他医疗人员可根据临床试验或者本领域其他公知的手段获知可使用的治疗有效量的范围。
以下通过实施例对本发明做进一步解释说明,但不构成对本发明的限制。应理解这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中为注明具体条件的试验方法,通常按照常规条件进行。
实施例1:化合物24的制备
化合物2的合成
将化合物1(2g,11.86mmol,1.0equiv.)溶于20mL吡啶中,然后加入三甲基乙酰氯(4.45mL,35.59mmol,3equiv.),室温搅拌过夜,得到N(2)单酰化和N(2),N(7)双酰化的混合物。旋除溶剂,残渣溶于氨水(25%NH
3,5mL)和甲醇(20mL)的混合溶剂中,室温搅拌30分钟,选择性的断开N(7)位的新戊酰基。过滤固体,用水洗涤滤饼(10mL×3),真空干燥,得到2.55g化合物2,黄色固体,产率85%。
1H NMR(400MHz,DMSO-d
6)δ12.32(s,1H),10.01(s,1H),7.54(d,J=3.6Hz,1H),6.53(d,J=3.5Hz,1H),1.24(s,9H).ESI-MS:m/z[M+H]
+calculated for C
11H
14ClN
4O
+253.09,found 253.06.
化合物3的合成
将化合物2(200mg,791.45μmol,1.0equiv.)溶于干燥的四氢呋喃(10mL)中,然后在N
2保护条件下加入N-碘代琥珀酰亚胺(213.68mg,949.74μmol,1.2equiv.),室温反应1小时。旋除溶剂,残渣溶于二氯甲烷(60mL)中,用饱和Na
2S
2O
3溶液(40mL×3)和盐水(30mL×3)洗涤,有机层用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=60:1-30:1),得到260mg化合物3,棕色固体,产率87%。
1H NMR(400MHz,DMSO-d
6)δ12.69(s,1H),10.09(s,1H),7.77(d,J=1.2Hz,1H),1.23(s,9H).ESI-MS:m/z[M-H]
-calculated for C
11H
11ClIN
4O
-376.97,found 377.08.化合物5的合成
将化合物3(255mg,673.54μmol,1.0equiv.),化合物4(157.08mg,707.21μmol,1.1equiv.)和K
2CO
3(279.26mg,2.02mmol,3.0equiv.)溶于干燥的DMF(5mL)中,室温搅拌24小时。将反应液逐滴加入水(15mL)和异丙醇(15mL)的混合溶液中。过滤固体,用水(15mL)洗涤滤饼,经真空干燥得到 323mg化合物5,白色固体,产率91%。
1H NMR(400MHz,DMSO-d
6)δ10.14(s,1H),8.05(s,1H),7.73(s,1H),5.46(s,2H),3.74(s,3H),2.33(s,3H),2.16(s,3H),1.21(s,9H).ESI-MS:m/z[M+H]
+calculated for C
20H
24ClIN
5O
2
+528.07,found 528.31.
化合物6的合成
将化合物5(2.0g,3.79mmol,1.0equiv.)溶于乙醇/水(20:1,42mL)的混合溶剂中,然后将ZnCl
2(2.58g,18.95mmol,5.0equiv.)加入到反应液中,加热至80℃搅拌20小时。冷却至室温,然后将反应液倒入水(50mL)中,过滤固体,用水(10mL×3)洗涤滤饼,经真空干燥得到1.44g化合物6,白色固体,产率86%。
1H NMR(400MHz,DMSO-d
6)δ8.07(s,1H),7.26(s,1H),6.71(s,2H),5.29(s,2H),3.73(s,3H),2.26(s,3H),2.17(s,3H).ESI-MS:m/z[M+H]
+calculated for C
15H
16ClIN
5O
+444.01,found 444.11.
化合物7的合成
将化合物6(1.0g,2.25mmol,1.0equiv.),CuI(42.93mg,225.39μmol,0.1equiv.),PPh
3(59.12mg,225.39μmol,0.1equiv.),10%Pd/C(66.73mg,56.35μmol,0.025equiv.)和K
2CO
3(342.65mg,2.48mmol,1.1equiv.)溶于DMF(12mL)和水(4mL)的混合溶剂中,N
2保护条件下,将溶于DMF(4mL)的对甲苯磺酸3-丁炔酯滴加至反应液中。将反应液加热至75℃搅拌3小时。反应液用硅藻土过滤,用乙酸乙酯洗涤硅藻土,然后用100mL乙酸乙酯稀释滤液。有机相用水(40mL×3)和盐水洗涤(40mL×3),无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(石油醚/乙酸乙酯=1:1-1:3),得到700mg化合物7,白色固体,产率74%。
1H NMR(400MHz,DMSO-d
6)δ8.10(s,1H),7.80(d,J=7.7Hz,2H),7.41(d,J=7.6Hz,2H),7.28(s,1H),6.75(s,2H),5.31(s,2H),4.14(t,J= 5.1Hz,2H),3.73(s,3H),2.77(t,J=5.1Hz,2H),2.33(s,3H),2.27(s,3H),2.17(s,3H).ESI-MS:m/z[M+H]
+calculated for C
26H
27ClN
5O
4S
+540.15,found 540.13.
化合物8的合成
将化合物7(406mg,751.80μmol,1.0equiv.)溶于DMF(8mL)中,然后将NaN
3(146.63mg,2.26mmol,3.0equiv.)加入至反应液中,将反应液加热至60℃搅拌4小时。冷却至室温后,将反应液倒入水中,乙酸乙酯(40mL×3)萃取三次,合并有机相,水洗盐洗,有机相用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(石油醚/乙酸乙酯=1:1-1:3),得到290mg化合物8,白色固体,产率94%。
1H NMR(400MHz,DMSO-d
6)δ8.06(s,1H),7.28(s,1H),6.71(s,2H),5.29(s,2H),3.73(s,3H),3.51(t,J=6.5Hz,2H),2.72(t,J=6.5Hz,2H),2.25(s,3H),2.17(s,3H).ESI-MS:m/z[M+H]
+calculated for C
19H
20ClN
8O
+411.14,found 411.03.
化合物9的合成
将化合物8(810mg,1.97mmol,1.0equiv.)溶于四氢呋喃(30mL)和水(2mL)的混合溶剂中,然后将PPh
3(1.55g,5.91mmol,3.0equiv.)加入至反应液中,室温搅拌过夜,旋除溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=30:1-5:1),得到480mg化合物9,白色固体,产率63%。
1H NMR(400MHz,DMSO-d
6)δ8.06(s,1H),7.30(s,1H),6.73(s,2H),5.28(s,2H),3.73(s,3H),2.92(t,J=6.9Hz,2H),2.65(t,J=7.0Hz,2H),2.25(s,3H),2.16(s,3H),1.23(s,2H).ESI-MS:m/z[M+H]
+calculated for C
19H
22ClN
6O
+385.15,found 385.10.
化合物11的合成
将化合物10(150mg,335.16μmol,1.0equiv.)和丙炔酸(30.95μL,502.74μmol,1.5equiv.)溶于二氯甲烷(15mL)中,然后将HATU(156.05mg,402.20μmol,1.2equiv.)和DIPEA(169.58μL,1.01mmol,3.0equiv.)加入至上述混悬液中,室温搅拌3小时。用100mL二氯甲烷稀释反应液,水洗并盐洗,有机相用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=70:1-40:1),得到105mg化合物11,黄色固体,产率63%。
1H NMR(400MHz,DMSO-d
6)δ10.15(s,1H),8.96(s,1H),8.09(d,J=2.7Hz,1H),7.90(d,J=9.0Hz,1H),7.52(dd,J=9.1,2.7Hz,1H),5.94–5.77(m,1H),4.62(s,1H),3.96–3.79(m,2H),3.75–3.60(m,2H),3.32–3.20(m,2H),3.21–3.06(m,2H),2.43(s,3H),2.31(s,3H),2.29–2.14(m,2H),2.00–1.84(m,2H),1.85–1.69(m,2H),1.68–1.50(m,2H).ESI-MS:m/z[M+H]
+calculated for C
27H
30N
7O
3
+500.24,found 500.17.
化合物12的合成
将化合物10(1.0g,2.23mmol,1.0equiv.)溶于DMF(15mL)中,然后将溴乙酸叔丁酯(398.86μL,2.68mmol,1.2equiv.)和DIPEA(1.13mL,6.70mmol,3.0equiv.)依次加入至反应液中,室温搅拌过夜。然后将反应液倒入水(50mL)中,过滤固体,滤饼用水(30mL)洗涤,经真空干燥得1.2g化合物12,黄色固体,产率95%。
1H NMR(400MHz,CDCl
3)δ8.82(s,1H),8.23(s,1H),8.15(d,J=9.1Hz,1H),8.06(d,J=2.8Hz,1H),7.32(dd,J=9.1,2.9Hz,1H),5.88(p,J=8.9Hz,1H),3.34–3.22(m,4H),3.20(s,2H),2.92–2.64(m,4H),2.55(s,3H),2.41–2.30(m,5H),2.11–2.02(m,2H),1.92–1.84(m,2H),1.74–1.67(m,2H),1.49(s,9H).ESI-MS:m/z[M+H]
+calculated for C
30H
40N
7O
4
+562.31,found 562.25.
化合物13的合成
将化合物12(1.0g,1.78mmol,1.0equiv.)溶于三氟乙酸(5mL)和二氯甲烷(5mL)的混合溶剂中,室温搅拌2小时。旋除反应液中的大部分溶剂,加入少量甲苯然后旋除,反复多次直至除去残留的三氟乙酸。该粗产物未经进一步纯化直接用于下一步反应。
化合物14的合成
将化合物13(255mg,504.37μmol,1.0equiv.)溶于干燥的二氯甲烷(20mL)中,然后依次将炔丙基胺(49.44μL,756.56μmol,1.5equiv.),HATU(287.67mg,757.5μmol,1.5equiv.)和DIPEA(448.24μL,2.52mmol,5.0equiv.)加入至反应液中,室温搅拌5小时。用100mL二氯甲烷稀释反应液,水洗并盐洗,有机相用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=60:1-30:1),得到185mg化合物14,黄色固体,产率68%。
1H NMR(400MHz,DMSO-d
6)δ10.09(s,1H),8.95(s,1H),8.20(t,J=5.7Hz,1H),8.06(d,J=2.7Hz,1H),7.85(d,J=9.0Hz,1H),7.48(dd,J=9.1,2.8Hz,1H),5.89–5.76(m,1H),3.89(dd,J=5.7,2.3Hz,2H),3.21(t,4H),3.07(t,J=2.3Hz,1H),3.02(s,2H),2.60(t,4H),2.42(s,3H),2.31(s,3H),2.28–2.14(m,2H),1.97–1.82(m,2H),1.82–1.68(m,2H),1.65–1.50(m,2H).ESI-MS:m/z[M+H]
+calculated for C
29H
35N
8O
3
+543.28,found 543.22.
化合物15的合成
将化合物13(257mg,508.33μmol,1.0equiv.)溶于干燥的二氯甲烷(20mL)中,然后依次将N-叔 丁氧羰基-1,2-乙二胺(97.73mg,609.99μmol,1.2equiv.),HATU(231.94mg,609.99μmol,1.2equiv.)和DIPEA(451.76μL,2.54mmol,5.0equiv.)加入至反应液中,室温搅拌过夜。用100mL二氯甲烷稀释反应液,水洗并盐洗,有机相用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=60:1-30:1),得到243mg化合物15,黄色固体,产率74%。
1H NMR(400MHz,DMSO-d
6)δ10.10(s,1H),8.96(s,1H),8.06(d,J=2.8Hz,1H),7.96–7.73(m,2H),7.47(dd,J=9.1,2.8Hz,1H),6.86(t,J=5.3Hz,1H),5.88–5.77(m,1H),3.29–3.11(m,6H),3.08–2.90(m,4H),2.61(s,4H),2.43(s,3H),2.32(s,3H),2.29–2.18(m,2H),1.95–1.84(m,2H),1.83–1.72(m,2H),1.64–1.55(m,2H),1.38(s,9H).ESI-MS:m/z[M+H]
+calculated for C
33H
46N
9O
5
+648.36,found 648.18.
化合物16的合成
按照化合物15的合成方法,由化合物13(166.52mg,329.36μmol,1.0equiv.)和[2-(2-氨基乙氧基)乙基]氨基甲酸叔丁酯(82.38mg,395.24μmol,1.2equiv.)为原料,得到150mg化合物16,黄色固体,产率66%。
1H NMR(400MHz,DMSO-d
6)δ10.10(s,1H),8.96(s,1H),8.07(d,J=2.6Hz,1H),7.85(d,J=9.1Hz,1H),7.80(s,1H),7.48(dd,J=9.0,2.6Hz,1H),6.77(t,J=4.9Hz,1H),5.87–5.75(m,1H),3.48–3.38(m,4H),3.31–3.18(m,6H),3.11–2.94(m,4H),2.63(s,4H),2.43(s,3H),2.31(s,3H),2.29–2.18(m,2H),1.95–1.83(m,2H),1.82–1.70(m,2H),1.65–1.53(m,2H),1.37(s,9H).ESI-MS:m/z[M+H]
+calculated for C
35H
50N
9O
6
+692.39,found 692.21.
化合物17的合成
按照化合物15的合成方法,由化合物13(300mg,593.38μmol,1.0equiv.)和2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯(176.82mg,712.06μmol,1.2equiv.)为原料,得到310mg化合物17,黄色固体,产率71%。
1H NMR(400MHz,DMSO-d
6)δ10.09(s,1H),8.95(s,1H),8.06(d,J= 2.6Hz,1H),7.85(d,J=9.0Hz,1H),7.77(s,1H),7.48(dd,J=9.1,2.7Hz,1H),6.74(t,J=5.4Hz,1H),5.87–5.77(m,1H),3.50(s,4H),3.45(t,J=5.8Hz,2H),3.39–3.36(m,2H),3.30–3.26(m,2H),3.21(s,3H),3.12–2.81(m,6H),2.62(s,3H),2.42(s,3H),2.31(s,3H),2.28–2.18(m,2H),1.93–1.83(m,2H),1.81–1.72(m,2H),1.64–1.54(m,2H),1.36(s,9H).ESI-MS:m/z[M+H]
+calculated for C
37H
54N
9O
7
+736.41,found 736.10.
化合物21的合成
化合物15(245mg,378.21μmol,1.0equiv.)溶于二氯甲烷(3mL)和三氟乙酸(3mL)的混合溶剂中,室温搅拌30分钟。然后旋除反应液中的大部分溶剂,加入少量甲苯然后旋除,反复多次直至除去残留的三氟乙酸,得到的化合物18的粗产物未经进一步纯化直接用于下一步反应。将残留物溶于二氯甲烷(15mL)中,然后加入DIPEA(312.54μL,1.89mmol,5.0equiv.),室温搅拌10分钟直至完全溶解,然后向反应液中加入丙炔酸(38.80μL,567.31μmol,1.5equiv.)和HATU(172.57mg,453.85μmol,1.2equiv.),室温搅拌6小时。用100mL二氯甲烷稀释反应液,水洗并盐洗,有机相用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=60:1-30:1),得到135mg化合物21,黄色固体,产率60%。
1H NMR(400MHz,DMSO-d
6)δ10.09(s,1H),8.95(s,1H),8.73(s,1H),8.06(d,J=2.9Hz,1H),7.99–7.76(m,2H),7.48(dd,J=9.1,2.9Hz,1H),5.90–5.77(m,1H),4.14(s,1H),3.32–3.07(m,8H),2.98(s,2H),2.60(s,4H),2.43(s,3H),2.31(s,3H),2.29–2.16(m,2H),1.97–1.83(m,2H),1.83–1.70(m,2H),1.66–1.53(m,2H).ESI-MS:m/z[M+H]
+calculated for C
31H
38N
9O
4
+600.30,found 600.26.
化合物22的合成
按照化合物21的合成方法,由化合物16(342mg,494.34μmol,1.0equiv.)为原料,得到148mg化合物22,黄色固体,产率47%。
1H NMR(400MHz,DMSO-d
6)δ10.09(s,1H),8.95(s,1H),8.74(t,1H),8.06(d,J=2.8Hz,1H),7.85(d,J=9.0Hz,1H),7.76(t,J=5.8Hz,1H),7.47(dd,J=9.1,2.9Hz,1H),5.88–5.77(m,1H),4.11(s,1H),3.47–3.40(m,4H),3.31–3.10(m,8H),2.99(s,2H),2.61(s,4H),2.42(s,3H),2.31(s,3H),2.29–2.17(m,2H),1.95–1.84(m,2H),1.82–1.71(m,2H),1.64–1.51(m,2H).ESI-MS:m/z[M+H]
+calculated for C
33H
42N
9O
5
+ 644.33,found 644.29.
化合物23的合成
按照化合物21的合成方法,由化合物17(310mg,421.26μmol,1.0equiv.)为原料,得到120mg化合物23,黄色固体,产率41.5%。
1H NMR(400MHz,DMSO-d
6)δ10.10(s,1H),8.95(s,1H),8.86–8.62(m,1H),8.06(d,J=2.7Hz,1H),7.85(d,J=9.0Hz,1H),7.77(t,J=5.6Hz,1H),7.48(dd,J=9.0,2.7Hz,1H),5.90–5.75(m,1H),4.11(s,1H),3.59–3.40(m,10H),3.30–3.19(m,6H),2.99(s,2H),2.61(s,4H),2.42(s,3H),2.31(s,3H),2.28–2.14(m,2H),1.94–1.82(m,2H),1.82–1.67(m,2H),1.65–1.50(m,2H).ESI-MS:m/z[M+H]
+calculated for C
35H
46N
9O
6
+688.36,found 688.20.
化合物24的合成
化合物9(100mg,259.83μmol,1.0equiv.)和化合物13(197.05mg,389.74μmol,1.5equiv.)溶于干燥的二氯甲烷(15mL)中,然后将HATU(148.19mg,389.74μmol,1.5equiv.)和DIPEA(226.29μL,1.30mmol,5.0equiv.)加入到反应液中,室温搅拌过夜。用100mL二氯甲烷稀释反应液,水洗并盐洗,有机相用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=50:1-20:1),得到80mg化合物24,黄色固体,产率35%。
1H NMR(400MHz,DMSO-d
6)δ10.07(s,1H),8.95(s,1H),8.01(s,1H),7.97(d,J=2.5Hz,1H),7.93(t,J=5.6Hz,1H),7.82(d,J=9.0Hz,1H),7.33(dd,J=9.1,2.4Hz,1H),7.25(s,1H),6.68(s,2H),5.82(p,J=8.7Hz,1H),5.24(s,2H),3.70(s,3H),3.41–3.34(m,2H),3.13(s,4H),3.00(s,2H),2.68–2.54(m,6H),2.43(s,3H),2.31(s,3H),2.29–2.18(m,5H),2.13(s,3H),1.93–1.82(m,2H),1.81–1.71(m,2H),1.64–1.51(m,2H).
13C NMR(100MHz,DMSO)δ202.92,169.58,163.78,161.24,160.00,159.03,158.72,155.23,153.87,153.80,152.07,149.21,144.76,143.78,142.55,135.73,131.49,129.68,125.50,124.95,123.85,115.61,107.96,107.05,95.52,89.77,74.82,61.66,60.26,53.34,53.06,48.66,46.86,37.93,31.78,28.04,25.58,20.48,14.10,13.32,10.69. ESI-HRMS:m/z[M+H]
+calculated for C
45H
51ClN
13O
4
+872.3870,found 872.3872.
实施例2:化合物25的制备
将化合物8(123.36mg,300.26μmol,1.0equiv.),化合物11(150mg,300.26μmol,1.0equiv.)和抗坏血酸钠(237.93mg,1.20mmol,4.0equiv.)溶解在t-BuOH/DCM(10mL/5mL)中,然后将CuSO
4(71.88mg,450.39μmol,1.5equiv.)溶解在5mL水中,滴加至上述反应液中,在N
2保护条件下将反应液加热至50℃并搅拌3小时。反应液冷却至室温后,旋除溶剂,残留物溶解在2M氨水(20mL)中,用二氯甲烷进行萃取,合并有机层,水洗并盐洗,有机相用无水Na
2SO
4干燥。减压除去有机溶剂,粗产物用硅胶柱层析进行纯化(二氯甲烷/甲醇=50:1-20:1),得到110mg化合物25,黄色固体,产率42%。
1H NMR(400MHz,DMSO-d
6)δ10.15(s,1H),8.96(s,1H),8.67(s,1H),8.10(s,1H),8.05(s,1H),7.90(s,1H),7.52(d,J=7.7Hz,1H),7.26(s,1H),6.70(s,2H),5.90–5.76(m,1H),5.27(s,2H),4.65(t,J=6.2Hz,2H),4.25(s,2H),3.81(s,2H),3.71(s,3H),3.23(s,4H),3.12(t,J=6.1Hz,2H),2.43(s,3H),2.34–2.22(m,8H),2.14(s,3H),1.95–1.87(m,2H),1.82–1.74(m,2H),1.63–1.56(m,2H).
13C NMR(100MHz,DMSO)δ202.94,163.79,161.21,160.01,159.88,153.84,153.79,152.11,149.26,143.30,131.93,129.42,125.51,123.84,107.81,94.97,87.75,75.89,60.28,53.42,48.96,46.88,31.78,28.04,25.61,21.13,14.10,13.33,10.71.ESI-HRMS:m/z[M+H]
+calculated for C
46H
49ClN
15O
4
+910.3775,found 910.3773.
实施例3:化合物26的制备
按照化合物25的合成方法,以化合物8(113.57mg,276.42μmol,1.0equiv.)和化合物14(150mg,276.42μmol,1.0equiv.)为原料,合成得到115mg化合物25,黄色固体,产率43.6%。
1H NMR(400MHz,DMSO-d
6)δ10.09(s,1H),8.95(s,1H),8.26(t,J=5.8Hz,1H),8.04(s,2H),7.99(s,1H),7.84(d,J=9.0Hz,1H),7.44(d,J=8.9Hz,1H),7.26(s,1H),6.69(s,2H),5.88–5.77(m,1H),5.26(s,2H),4.55(t,J=6.6Hz,2H),4.36(d,J=5.7Hz,2H),3.71(s,3H), 3.17(s,4H),3.10–2.89(m,4H),2.57(s,4H),2.42(s,3H),2.38–2.18(m,8H),2.14(s,3H),1.93–1.83(m,2H),1.81–1.71(m,2H),1.62–1.53(m,2H).
13C NMR(100MHz,DMSO)δ202.93,169.61,163.79,161.23,160.01,159.03,158.73,155.23,153.86,153.79,152.14,149.24,145.37,144.75,143.84,142.56,135.79,131.90,129.68,125.51,125.13,123.82,123.29,115.64,107.85,107.03,95.08,88.04,75.73,61.50,60.28,53.36,53.04,48.64,46.88,34.57,31.78,28.03,26.82,25.59,21.36,14.10,13.33,10.70.ESI-HRMS:m/z[M+H]
+calculated for C
48H
54ClN
16O
4
+953.4197,found 953.4205.
实施例4:化合物27的制备
按照化合物25的合成方法,以化合物8(68.5mg,166.75μmol,1.0equiv.)和化合物21(100mg,166.75μmol,1.0equiv.)为原料,合成得到77mg化合物27,黄色固体,产率45.7%。
1H NMR(400MHz,DMSO-d
6)δ10.09(s,1H),8.92(s,1H),8.64(s,1H),8.58(t,J=5.3Hz,1H),8.04(s,1H),8.00(s,1H),7.95–7.78(m,2H),7.42(dd,J=8.8,1.7Hz,1H),7.20(s,1H),6.69(s,2H),5.88–5.77(m,1H),5.24(s,2H),4.60(t,J=6.5Hz,2H),3.71(s,3H),3.48–3.35(m,4H),3.16–3.03(m,6H),2.96(s,2H),2.55(s,4H),2.43(s,3H),2.30–2.20(m,8H),2.15(s,3H),1.94–1.85(m,2H),1.83–1.73(m,2H),1.63–1.54(m,2H).
13C NMR(100MHz,DMSO)δ202.95,169.84,163.79,161.22,160.50,159.98,158.99,158.65,155.20,153.84,153.74,152.11,149.24,144.81,143.78,143.18,142.55,135.78,131.82,129.67,127.00,125.51,125.13,123.84,115.50,107.79,107.01,94.96,87.61,75.80,65.49,60.28,53.40,52.98,48.99,48.61,46.86,38.75,38.62,31.78,28.04,25.61,21.13,14.06,13.33,10.70.ESI-HRMS:m/z[M+H]
+calculated for C
50H
57ClN
17O
5
+1010.4412,found 1010.4421.
实施例5:化合物28的制备
按照化合物25的合成方法,以化合物8(89.35mg,217.48μmol,1.0equiv.)和化合物22(140mg, 217.48μmol,1.0equiv.)为原料,合成得到90mg化合物28,黄色固体,产率39.2%。
1H NMR(400MHz,DMSO-d
6)δ10.09(s,1H),8.94(s,1H),8.62(s,1H),8.40(t,J=5.0Hz,1H),8.05(s,2H),7.86(d,J=8.3Hz,1H),7.79(s,1H),7.46(d,J=7.7Hz,1H),7.23(s,1H),6.69(s,2H),5.88–5.75(m,1H),5.25(s,2H),4.61(t,J=6.0Hz,2H),3.72(s,3H),3.54–3.41(m,6H),3.31–3.27(m,2H),3.19(s,4H),3.11–3.04(m,2H),3.00(s,2H),2.60(s,4H),2.43(s,3H),2.33–2.20(m,8H),2.15(s,3H),1.92–1.84(m,2H),1.81–1.73(m,2H),1.61–1.53(m,2H).
13C NMR(100MHz,DMSO)δ202.92,167.43,163.79,161.23,160.22,159.99,159.02,158.69,155.22,153.84,153.76,152.13,149.25,144.76,143.83,143.14,142.55,135.82,131.99,129.13,126.94,125.50,125.16,123.84,115.61,107.82,107.03,94.98,87.67,75.80,69.25,69.06,65.50,60.28,53.38,52.99,49.01,48.63,46.85,38.74,38.66,31.77,28.03,25.58,21.11,14.07,13.32,10.70.ESI-HRMS:m/z[M+H]
+calculated for C
52H
61ClN
17O
6
+1054.4674,found 1054.4683.
实施例6:化合物29的制备
按照化合物25的合成方法,以化合物8(73.47mg,178.83μmol,1.0equiv.)和化合物23(123mg,178.83μmol,1.0equiv.)为原料,合成得到88mg化合物29,黄色固体,产率44.8%。
1H NMR(400MHz,DMSO-d
6)δ10.06(s,1H),8.94(s,1H),8.62(s,1H),8.36(t,J=4.9Hz,1H),8.05(s,2H),7.85(d,J=8.8Hz,1H),7.76(s,1H),7.46(d,J=8.1Hz,1H),7.23(s,1H),6.67(s,2H),5.88–5.74(m,1H),5.26(s,2H),4.61(t,J=6.0Hz,2H),3.72(s,3H),3.53(s,6H),3.47–3.39(m,4H),3.29–3.25(m,2H),3.19(s,4H),3.09(t,J=6.0Hz,2H),2.99(s,2H),2.60(s,4H),2.42(s,3H),2.34–2.19(m,8H),2.15(s,3H),1.96–1.84(m,2H),1.83–1.72(m,2H),1.64–1.53(m,2H).
13C NMR(100MHz,DMSO)δ202.89,169.55,163.81,161.24,160.19,160.00,159.03,158.69,155.23,153.84,153.78,152.14,149.27,144.78,143.84,143.15,142.55,135.84,131.84,129.69,126.93,125.50,125.16,123.86,115.62,107.84,107.05,95.00,87.69,75.81,70.02,69.97,69.48,69.28,61.57,60.28,53.40,53.00,49.02,48.70,46.87,38.69,38.61,31.76,28.03,25.57,21.13,14.07,13.32,10.71.ESI-HRMS:m/z[M+H]
+calculated for C
54H
65ClN
17O
7
+1098.4936,found 1098.4947.
实施例7:表面等离子共振法(SPR)测定化合物与HSP90α的结合亲和力
打开Biacore T200控制软件按照标准流程安装CM5芯片,准备开始正式实验,缓冲液以较高的流速冲洗整个系统内部的流路系统。根据样本量选择合适的程序。开始捕获芯片,偶联缓冲液为PBS(pH7.4)。准备足够体积的样品,EDC/NHS,blocking buffer。开始偶联程序,最终配体偶联量约为12500RU。偶偶联完成后开始检测,缓冲液换为含1%DMSO PBS(pH7.4),设定分析物结合时间为120s,流速为30μL/min;解离时间为300s,流速为30μL/min;再生时间30s,流速为30μL/min。按照要求准备需要检测的对应样品,开始自动运行程序进行检测。结果分析,根据运行结果,进行数据的拟合分析,得到最终的亲和力拟合KD值。
图2结果表明,与HSP90抑制剂BIIB021相比,设计合成的小分子HEMTACs对HSP90均有很好的亲和力,表明对BIIB021的N7位的改造并在该位点引入linker对小分子HEMTACs与HSP90结合的影响很小,证明了前期设计的合理性。
实施例8:Western blot实验
用化合物对B16F10细胞进行不同浓度和不同时间的处理后,通过Western blot实验测定细胞内CDK4和CDK6蛋白的水平。首先提取细胞蛋白并进行蛋白定量:用RIPA细胞裂解液(加蛋白酶抑制剂)裂解细胞,收集蛋白,并用BCA蛋白定量测定试剂盒进行定量,定量成同一浓度。蛋白变性:将蛋白置于100℃水浴8分钟,使蛋白变性。上样并跑胶:每孔上样量一般为20μL,上层浓缩胶的电泳电压为75V,下层分离胶的电泳电压为120V,待40KD的蛋白marker下至凝胶末端处1cm左右,停止电泳。转膜:使用湿转转膜仪进行转膜,PVDF膜要事先用甲醇浸泡,恒流250mA,转膜90分钟。封闭:将PVDF膜置于BSA封闭液中封闭1h(摇床慢摇)。孵育一抗:按照说明书稀释一抗,加入一抗后,4℃孵育过夜。洗膜:用TBST洗膜液洗涤3次,每次洗涤10分钟。孵育二抗:加入二抗后,室温下摇床孵育1h。洗膜:用TBST洗膜液洗涤3次,每次洗涤10分钟。曝光:将ECL显影液A液和B液等体积混合,进行曝光。
用小分子HEMTACs处理B16F10黑色素瘤细胞24h后,Western blot结果(图3)表明CDK4/6蛋白水平呈剂量依赖性降低,其中化合物26的降解活性最好,大大增强了BIIB021的降解活性。化合物26诱导B16F10细胞CDK4和CDK6降解的DC
50值(导致50%蛋白质降解的药物浓度)分别约为26nM和19nM。此外,用0.5μM化合物26处理细胞可在12小时内诱导CDK4/6的降解。以上结果说明了我们基于HSP90抑制剂BIIB021成功的建立了一种新的蛋白降解方法。
实施例9:小鼠体内抗肿瘤实验
在C57BL/6小鼠前肢腋下皮下注射B16F10细胞(10
6个细胞/小鼠),建立小鼠B16F10黑色素瘤异种移植模型。当肿瘤体积达到100-200mm
3时,将小鼠随机分为四组(n=6)。连续两周每天腹腔注射化合物,每两天测量小鼠体重和肿瘤体积。肿瘤体积是通过用游标卡尺沿两个正交轴来测量肿瘤的长度和宽度,并用公式V(mm
3)=(长×宽
2)/2计算小鼠的肿瘤体积。
根据图4可知,化合物26(40mg/kg)能够显著抑制黑色素瘤的生长,并且化合物26(20mg/kg)的体内抑瘤作用优于HSP90抑制剂BIIB021(20mg/kg)。此外,化合物26导致小鼠的体重有轻微减轻,但在所有治疗组中都没有显示出其他的毒性迹象。该实验说明了我们设计合成的靶向CDK4/6的小分子HEMTAC 26具有体内抗黑色素瘤的作用。
上述实施例只为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰,都应涵盖在本发明的保护范围之内。
Claims (10)
- 一种化合物,其特征在于,其具有如下式(I)所述结构:R 1-L-R 2式(I)其中:(a)R1是靶蛋白的配体/结合物;(b)R2是HSP90的配体;(c)L是连接链,所述R1和R2通过L连接起来。
- 如权利要求1所述的化合物,其特征在于,所述靶蛋白包括激酶、G蛋白偶联受体、转录因子、磷酸酶及RAS超家族成员;所述R1选自:靶向以下的化合物:激酶、G蛋白偶联受体、转录因子、磷酸酶及RAS超家族成员;优选的,所述R1是帕博西尼。
- 如权利要求1-4任一项所述化合物,其特征在于,所述化合物还包括其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物。
- 权利要求1-5任一项所述化合物在制备肿瘤、炎症、免疫相关疾病药物中的应用;优选的,所述疾病还包括与细胞周期依赖性蛋白激酶4和6相关的疾病。
- 一种药物组合物,其特征在于,其包含权利要求1-5任一项所述化合物。
- 一种药物制剂,其特征在于,其包含权利要求1-5任一项所述化合物和至少一种药学上可接受的药物非活性成分。
- 如权利要求8所述药物制剂,其特征在于,所述药物非活性成分是药学上通常使用的载体、赋形剂及稀释剂。
- 一种治疗肿瘤、炎症、免疫相关疾病的方法,其特征在于,所述方法包括向受试者施用治疗有效量的权利要求1-4任一项所述化合物、权利要求7所述药物组合物或权利要求8或9所述药物制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22930459.7A EP4306528A1 (en) | 2022-03-11 | 2022-05-17 | Hemtac small molecule degradation agent and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210241970.5 | 2022-03-11 | ||
CN202210241970.5A CN114907386B (zh) | 2022-03-11 | 2022-03-11 | 一种hemtac小分子降解剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023168830A1 true WO2023168830A1 (zh) | 2023-09-14 |
Family
ID=82762960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/093374 WO2023168830A1 (zh) | 2022-03-11 | 2022-05-17 | 一种hemtac小分子降解剂及其应用 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4306528A1 (zh) |
CN (1) | CN114907386B (zh) |
WO (1) | WO2023168830A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114907386B (zh) * | 2022-03-11 | 2023-03-31 | 山东大学 | 一种hemtac小分子降解剂及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106458993A (zh) * | 2014-04-14 | 2017-02-22 | 阿尔维纳斯股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
CN108137507A (zh) * | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
CN108601764A (zh) * | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
CN109952299A (zh) * | 2016-09-14 | 2019-06-28 | 邓迪大学 | 用于制备蛋白降解靶向嵌合体的氟代羟脯氨酸衍生物 |
WO2021143816A1 (zh) * | 2020-01-16 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用 |
CN113924123A (zh) * | 2019-04-09 | 2022-01-11 | 珃诺生物医药科技(杭州)有限公司 | 用于靶向蛋白降解的方法和组合物 |
CN114907386A (zh) * | 2022-03-11 | 2022-08-16 | 山东大学 | 一种hemtac小分子降解剂及其应用 |
-
2022
- 2022-03-11 CN CN202210241970.5A patent/CN114907386B/zh active Active
- 2022-05-17 WO PCT/CN2022/093374 patent/WO2023168830A1/zh active Application Filing
- 2022-05-17 EP EP22930459.7A patent/EP4306528A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106458993A (zh) * | 2014-04-14 | 2017-02-22 | 阿尔维纳斯股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
CN108601764A (zh) * | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
CN108137507A (zh) * | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
CN109952299A (zh) * | 2016-09-14 | 2019-06-28 | 邓迪大学 | 用于制备蛋白降解靶向嵌合体的氟代羟脯氨酸衍生物 |
CN113924123A (zh) * | 2019-04-09 | 2022-01-11 | 珃诺生物医药科技(杭州)有限公司 | 用于靶向蛋白降解的方法和组合物 |
WO2021143816A1 (zh) * | 2020-01-16 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用 |
CN114907386A (zh) * | 2022-03-11 | 2022-08-16 | 山东大学 | 一种hemtac小分子降解剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114907386B (zh) | 2023-03-31 |
CN114907386A (zh) | 2022-08-16 |
EP4306528A1 (en) | 2024-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2285693C2 (ru) | Производные пиридина и хинолина, способ их получения, фармацевтическая композиция, применение соединений для лечения заболеваний, ассоциированных с dpp-iv | |
KR20220151616A (ko) | 에스트로겐 수용체-연관 질환의 치료 방법 | |
AU2007238676A1 (en) | Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders | |
WO2018219281A1 (zh) | 一类4‐嘧啶二胺类小分子有机化合物及其衍生物及其应用 | |
JP2019508475A (ja) | 化合物(s)−4−((s)−3−フルオロ−3−(2−(5,6,7,8−テトラヒドロ−1,8−ナフチリジン−2−イル)エチル)ピロリジン−1−イル)−3−(3−(2−メトキシエトキシ)フェニル)ブタン酸のクエン酸塩 | |
CN113993845A (zh) | 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物 | |
KR20220034129A (ko) | 에스트로겐 수용체 길항제 요법 | |
TWI293301B (en) | A1 adenosine receptor antagonists | |
RU2727194C2 (ru) | Гетероциклические соединения для лечения заболевания | |
WO2022174525A1 (zh) | 一类化合物及其制备方法和用途 | |
WO2022174526A1 (zh) | 一类化合物及其用于结直肠癌的医药用途 | |
WO2023168830A1 (zh) | 一种hemtac小分子降解剂及其应用 | |
WO2024031965A1 (zh) | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 | |
WO2023077739A1 (zh) | 一种喹诺酮衍生物及其制备方法和用途 | |
AU2005321915A1 (en) | Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto | |
JP6298172B2 (ja) | Gpr142アゴニスト化合物 | |
CN115477634B (zh) | 用于镇痛的化合物及其医药用途 | |
WO2023098852A1 (en) | Crystal forms of thienoimidazole compound and preparation method thereof | |
CN101253146A (zh) | 用于治疗肥胖症及相关病症的新的氨基酸衍生物 | |
CN117229291B (zh) | 内体-溶酶体转运靶向嵌合体降解剂及其制备方法与应用 | |
US20240252657A1 (en) | Hemtac small-molecule degradation agent and application thereof | |
CN115433160B (zh) | 镇痛活性化合物及其医药用途 | |
KR102576102B1 (ko) | Uch37 탐지용 프로브 및 이의 용도 | |
WO2022184111A1 (zh) | 与tau蛋白结合的小分子化合物 | |
CN111559982B (zh) | 2-(2-取代-4-羟基嘧啶-5-甲酰胺基)乙酸类化合物及其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2022930459 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22930459 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18557959 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022930459 Country of ref document: EP Effective date: 20231012 |